198084-13-8

Usage

Uses

Used in Pharmaceutical Industry:
(4-Pyrimidin-5-ylphenyl)methanol is used as a building block for the synthesis of various pharmaceuticals due to its unique structure and properties. It contributes to the development of new drugs and medicinal compounds, enhancing the therapeutic potential of existing treatments.
Used in Agrochemical Industry:
In the agrochemical sector, (4-Pyrimidin-5-ylphenyl)methanol serves as a key component in the creation of novel agrochemicals. Its incorporation into these products can lead to advancements in crop protection and pest management strategies, ultimately benefiting agricultural productivity.
Used in Organic Synthesis:
(4-Pyrimidin-5-ylphenyl)methanol is utilized as a reagent in organic synthesis, facilitating the production of a wide range of organic compounds. Its unique structure allows for versatile reactions, making it an indispensable tool in the synthesis of complex organic molecules.
Used in Chemical Research:
(4-PYRIMIDIN-5-YLPHENYL)METHANOL also finds application in chemical research, where it is employed to study various chemical reactions and mechanisms. Its unique properties make it a valuable subject for investigation, contributing to the advancement of chemical knowledge and understanding.
Overall, (4-Pyrimidin-5-ylphenyl)methanol is a multifaceted compound with broad applications across different industries, underpinning its significance in the realm of chemical science and technology.

InChI:InChI=1/C11H10N2O/c14-7-9-1-3-10(4-2-9)11-5-12-8-13-6-11/h1-6,8,14H,7H2

Upstream product

• 7732-18-5 water 
• 198084-12-7 4-(pyrimidin-5-yl)benzaldehyde 
• 893734-17-3 methyl 4-(pyrimidin-5-yl)benzoate 
• 619-42-1 4-methoxycarbonylphenyl bromide 

Relevant academic research and scientific papers

PYRROLIDINE GLYCOSIDASE INHIBITORS

Compounds of formula (I) wherein A, W, R3b, Z and p have the meaning according to the claims can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.

HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS

ABSTRACT The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.

C-KIT MODULATORS AND METHODS OF USE

The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. Even more specifically, the invention

SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL) BENZOHETEROARYL COMPOUNDS

This invention is directed to an (aminoiminomethyl or aminomethyl) benzoheteroaryl compound of formula I which is useful for inhibiting the activity of Factor Xa by combining said compound with a composition containing Factor Xa. The present invention is also directed to compositions containing compounds of the formula I, methods for their preparation, their use, such as in inhibiting the formation of thrombin or for treating a patient suffering from, or subject to, a disease state associated with a physiologically detrimental excess amount of thrombin.

Substituted (aminoiminomethyl or aminomethyl) dihydrobenzofurans and benzopyrans

This invention is directed to substituted (aminoiminomethyl or aminomethyl) dihydrobenzofurans and benzopyrans that inhibit Factor Xa, pharmaceutical compositions comprising these compounds and their use for inhibiting Factor Xa or treating pathological conditions in a patient that may be ameliorated by administration of such compounds. This invention is also is also directed to substituted (aminoiminomethyl or aminomethyl) dihydrobenzofurans and benzopyrans which directly inhibit both Factor Xa and Factor IIa (thrombin), to pharmaceutical compositions comprising these compounds, to intermediates useful for preparing these compounds and to a method of simultaneously directly inhibiting both Factor Xa and Factor IIa (thrombin).

Inhibitors of farnesyl-protein transferase

The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invent